Colossal Biosciences Announces $200M Series C and $10.2B Valuation

Gunderson Dettmer represented client Colossal Biosciences, the world’s first de-extinction company, in its $200 million Series C financing led by TWG Global. Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. This latest financing places the company at a $10.2 billion valuation and will be used to advance its genetic engineering technologies while pioneering new revolutionary software, wetware and hardware solutions, which have applications beyond de-extinction including species preservation and human healthcare.

In the announcement of the transaction, Colossal CEO and co-founder Ben Lamm said, “Our recent successes in creating the technologies necessary for our end-to-end de-extinction toolkit have been met with enthusiasm by the investor community. TWG Global and our other partners have been bullish in their desire to help us scale as quickly and efficiently as possible. This funding will grow our team, support new technology development, expand our de-extinction species list, while continuing to allow us to carry forth our mission to make extinction a thing of the past.”

The Gunderson Dettmer deal team was led by John Tolpa and included Will Fogarty, Seth Bertolucci and Stephanie Henderson.

Companies
Colossal Biosciences